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AbstrACt
Introduction In the past decades, short-term results 
after solid organ transplantation have markedly improved. 
Disappointingly, this has not been accompanied by parallel 
improvements in long-term outcomes after transplantation. 
To improve graft and recipient outcomes, identification 
of potentially modifiable risk factors and development of 
biomarkers are required. We provide the rationale and 
design of a large prospective cohort study of solid organ 
transplant recipients (TransplantLines).
Methods and analysis TransplantLines is designed 
as a single-centre, prospective cohort study and 
biobank including all different types of solid organ 
transplant recipients as well as living organ donors. 
Data will be collected from transplant candidates before 
transplantation, during transplantation, at 3 months, 6 
months, 1 year, 2 years and 5 years, and subsequently 
every 5 years after transplantation. Data from living 
organ donors will be collected before donation, during 
donation, at 3 months, 1 year and 5 years after donation, 
and subsequently every 5 years. The primary outcomes 
are mortality and graft failure. The secondary outcomes 
will be cause-specific mortality, cause-specific graft 
failure and rejection. The tertiary outcomes will be other 
health problems, including diabetes, obesity, hypertension, 
hypercholesterolaemia and cardiovascular disease, 
and disturbances that relate to quality of life, that is, 
physical and psychological functioning, including quality 
of sleep, and neurological problems such as tremor and 
polyneuropathy.
Ethics and dissemination Ethical approval has been 
obtained from the relevant local ethics committee. The 
TransplantLines cohort study is designed to deliver 
pioneering insights into transplantation and donation 
outcomes. The study design allows comprehensive data 
collection on perioperative care, nutrition, social and 
psychological functioning, and biochemical parameters. 
This may provide a rationale for future intervention 
strategies to more individualised, patient-centred 
transplant care and individualisation of treatment.
trial registration number NCT03272841. 
bACkground  
Solid organ transplantation is the preferred 
treatment for end-stage organ failure. During 
the past decades, advances in immunosup-
pressant medications, treatment of infections, 
perioperative medical care and surgical tech-
niques (including living donation) have led to 
important improvements in early post-trans-
plant graft and patient survival.1 However, in 
the long term, graft failure is a major cause 
of patient mortality and morbidity in all 
types of transplantation.2–4 For example, in 
renal transplant recipients, half of the cadav-
eric renal allografts fail within a timeframe 
of 10 years.5 Apart from reduced survival, 
transplant recipients often develop health 
problems that greatly reduce their perceived 
quality of life (figure 1).6–8 
The multitude of health problems that 
recipients experience after transplantation 
includes, among others, obesity, diabetes, 
hypertension, heart failure and malignan-
cies.9–11 These are likely the consequence of a 
combination of factors, including (1) contin-
uous exposure to treatment with immuno-
suppressive drugs necessary for prevention of 
strengths and limitations of this study
 ► This is a large biobank and cohort study with ex-
tensive data collection on a myriad topics related to 
transplantation and/or donation.
 ► The study included all types of solid organ transplant 
recipients.
 ► The study has a long follow-up to assess many rele-
vant clinical outcomes.
 ► This is a single-centre study.
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rejection of the transplanted organ, (2) damage induced 
by pre-existing exposure to end-stage organ failure, and 
(3) adverse lifestyle and environmental factors, all poten-
tially expressed against (4) a background of increased 
(epi)genetic susceptibility. Among these, immunosup-
pressive treatment, adverse lifestyle and environmental 
factors are good candidates for modification to decrease 
the load of post-transplant health problems. It should be 
realised that immunosuppressive treatment is currently 
mainly ‘one-size fits all’. Hence, improvement can be 
achieved by the development of biomarkers that can allow 
for recognition of transplant recipients in which immu-
nosuppressive load can be safely reduced or in which 
certain drugs can better be avoided, and of biomarkers 
which can guide such individualised immunosuppressive 
treatment. To improve long-term transplant outcomes, it 
is imperative to identify modifiable risk factors, especially 
among those recipients who are at increased risk.
To date, it is largely unknown in which transplant 
recipients immunosuppressive medication can be safely 
reduced to prevent the development of health problems. 
Furthermore, in terms of healthcare costs, it is important 
to prevent recurrent hospital admissions, retransplanta-
tions or—in the case of kidney transplantation—return to 
dialysis, which are all associated with very high expenses.12 
To effectively develop interventions to reduce mortality 
and morbidity after transplantation, more research is 
necessary on clinical and biochemical risk factors present 
in transplant recipients. Also, the use of living donors for 
kidney and liver transplantation requires a living donor 
programme with good long-term outcomes for the donor 
and the recipient. Living kidney donors, for example, 
have an increased risk of end-stage renal disease,13 14 
while only registry data exist on the effect of living donor 
characteristics on recipient outcomes.15 16
Until now, many registries and large cohort studies 
focus on one type of solid organ transplantation, limiting 
comparability between different transplant populations. 
As a result, studies investigating biomarkers, quality 
of life, and the development of health problems and 
adverse outcomes across different solid organ transplant 
populations are scarce. Despite the differences which 
exist in patient characteristics and treatment after 
different solid organ transplantations, there are many 
similarities in health problems that occur among subtypes 
of transplantation. The objective of the TransplantLines 
study is to identify the risk factors for the development 
of long-term health problems after transplantation and 
to develop new interventions to improve outcome, both 
combined for all solid organ transplant recipients as well 
as specific for each subtype of transplantation.
MEthods/dEsIgn
study design and setting
The TransplantLines study is a unique, novel prospec-
tive biobank and cohort study which aims to provide a 
better understanding of the causes of disease-related and 
ageing-related outcomes and health problems, both phys-
ical and psychological, in solid organ transplant recipients 
and donors. The University Medical Center Groningen 
(UMCG) is the largest transplantation centre in the Neth-
erlands, and the only Dutch centre that covers all types 
of solid organ transplantation, as well as living kidney 
and liver donation programmes. All participants will give 
written informed consent on enrolment. Follow-up and 
prospective events will be recorded over time. An overall 
participation rate of 85% is expected across the different 
transplant populations and a total number of 3000 partic-
ipants is aimed.
transplant patients
The study population comprises all solid organ transplant 
recipients, that is, heart, lung, kidney, liver and small 
bowel transplant recipients. Both new transplant candi-
dates as well as transplant recipients are eligible to partic-
ipate in the study. Participants of all ages will be included 
in TransplantLines. Children (age <18 years) will be 
eligible for participation on consent by a legal represen-
tative (<12 years) or a shared consent of both the child 
and the legal representative (≥12 years). The study will 
also include candidates for retransplantation. Exclusion 
criteria for participation in the TransplantLines study 
will be no mastery of the Dutch language or no capability 
to intellectually comprehend questionnaires or physical 
tests.
Living donors
Living kidney and liver donors will also be included in 
the study. The goal of including donors is to study the 
effects of donation and improve living donor safety, and 
donors will serve as controls for their recipients, allowing 
for matched longitudinal analyses. Prospective living 
kidney and liver donor candidates (≥18 years old) will be 
eligible to participate in the study, as well as living organ 
donors who have donated an organ prior to the start of 
the TransplantLines study. Exclusion criteria will be no 
mastery of the Dutch language or no capability to intel-
lectually comprehend questionnaires or physical tests.
Figure 1 Overview of different health problems that arise in 
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transplant recipients timeline
All participants of the TransplantLines study will be exam-
ined at fixed timepoints, as shown in figure 2. Transplant 
candidates will be first seen at pretransplant screening. 
Prior to transplantation, all transplant candidates 
undergo routine clinical screening. Generally, transplant 
candidates will be transplanted if surgery risks and trans-
plant benefit are optimised, based on an individualised 
multidisciplinary clinical decision. Further study visits will 
be performed at the time of transplantation, at 3 months, 
6 months, 12 months and 2 years after transplantation, 
and hereafter follow-up will be performed at 5 years after 
transplantation and every consecutive 5 years. At time of 
transplantation means during operation prior to surgical 
incision. At that timepoint, the blood samples are being 
drawn by the anaesthesiologists taking care of the patient. 
The difference with this sample compared with other 
previous samples is that this sample is taken during 
the operation, whereas the other samples are not. For 
example, a kidney transplant candidate can be screened 
and included in the TransplantLines study, but may need 
to wait 2 years on the waiting list prior to receiving the 
actual transplantation. Since we realise that a study of this 
size and duration combined with the frequency of study 
visits will result in lower subject adherence, we estimate a 
10% dropout overall in follow-up in this group of trans-
plant candidates.
Transplant recipients with a functional graft for at 
least 1 year post-transplantation and who received a solid 
organ transplant prior to the start of the TransplantLines 
study will be included at the next outpatient clinic visit. 
Henceforth, patients will be examined every 5 years and 
follow-up samples will be collected. Aside from the fixed 
timepoints, biobank samples of transplant recipients 
will be collected at the time of protocol biopsies that 
are performed in the kidney transplant programme (6 
months after transplantation) and the heart transplant 
programme (repeatedly during the first year after trans-
plantation), and if a biopsy is taken, on clinical indica-
tion, usually because of worsening of transplant function, 
with suspicion of acute or chronic rejection.
If a subject gets retransplanted with the same kind of 
organ, this will be classified as graft failure and the end 
of follow-up. Subjects will not be included in the primary 
database twice. Yet we will allow for inclusion of subjects 
retransplanted with the same kind of organ with a new 
identification in the transplant candidate group, but this 
will be with the intention to build over time a separate 
cohort with data and a biobank on retransplantations. 
When a transplant recipient is later on transplanted with 
another kind of organ, follow-up will be for the initially 
transplanted organ. Transplant recipients receiving a 
combined transplantation, for example, kidney-pancreas 
and kidney-liver, will be treated as separate groups, not 
to be included in overall analyses for the much larger 
groups of subjects with single transplanted organs.
In case a transplant recipient moves to another region 
of the Netherlands or abroad, the transplant recipient 
will always require continued medical care and follow-up 
by a medical specialist, who will require thorough medical 
information on the patient and the transplanted organ, 
to allow for continued dedicated care. Therefore, the 
medical specialist who will continue care will seek contact 
for information, and it will usually be possible to continue 
follow-up on long-term outcome and events via this 
medical specialist. So follow-up is usually assured and loss 
to follow-up will be rare. Since study visits are combined 
with routine clinical visits, subjects who move out of our 
region will be excluded from further study visits for the 
TransplantLines study.
Living donors timeline
All donors of the TransplantLines study will be examined 
at fixed timepoints, as shown in figure 2. The first study visit 
of donor candidates will occur at predonation screening. 
Prior to donation, all candidates undergo routine clinical 
screening. Generally, donors will be accepted if surgery 
risks and transplant benefit are optimised, based on an 
individualised multidisciplinary clinical decision taking 
national and international guidelines into account.17 18 
Subsequently, study visits will be performed at the time of 
nephrectomy and at 3 months postdonation. At 12 months 
postdonation, donors will fill in a questionnaire, and at 
5 and 10 years postdonation there will be another study 
visit. Hereafter follow-up will be performed every 5 years. 
Living organ donors who have donated an organ prior to 
the start of the TransplantLines study will be included at 
their next donor follow-up visit to their outpatient clinic.
Figure 2 Flow chart of the different visits in the TransplantLines study. At every study visit, biobank, general tests and 
questionnaires will be performed. Specifically addition at each timepoints; at time of transplantation, perioperative residual 
material will be collected. At 3 months after transplantation, cognitive protocol will be performed. At 6 months, physical protocol 
will be carried out. At 12 months, randomisation to physical or cognitive protocol will occur. At 2 years after transplantation, a 
limited set of tests will be executed. Follow-up will be performed every 5 years.
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Patient and public involvement
The aim of the TransplantLines study is to provide a 
better understanding of the causes of disease-related 
and ageing-related outcomes and health problems. This 
aim was derived from patient surveys, and parts of the 
collected data are codesigned by patients and healthcare 
professionals. Because of its scope, patients will play a role 
in the organisation of the study, helping with recruitment 
and conduct of the study. Also, students from a broad 
range of studies will play a role in the organisation of 
the study, for example, master students from medicine, 
biomedical sciences, neuropsychology, psychology, phys-
ical therapy, communication sciences, dietitian students 
and laboratory technician students. Patients and collab-
orators will be informed of major study results by press 
releases from the UMCG.
data collection
Biobank
Blood, 24-hour urine, faeces, nails and hair will be 
collected from the participants at each TransplantLines 
visit. Participants will be instructed to collect a 24-hour 
urine sample according to strict protocol on the day 
before their visit to the outpatient clinic, that is, discard 
their morning urine specimen, collect all subsequent 
urine throughout the next 24 hours and include the next 
morning’s first specimen of the day of the visit to the outpa-
tient clinic. Blood will be drawn after an overnight fasting 
period of 8–12 hours in the morning after completion of 
the 24-hour urine collection. Blood drawing and receipt 
of the collected 24-hour urine samples are performed by 
experienced nurses at our outpatient clinic.
As blood samples, one serum tube of 10 mL, two 
EDTA samples of 10 mL, one citrate tube of 6 mL, one 
lithium-heparin tube of 10 mL and one PAXgene tube 
of 10 mL will be collected from each participant at each 
TransplantLines visit. Subsequently, tubes will be centri-
fuged by technicians at 1300 g for 10 min, except for the 
citrate tube which is centrifuged at 2500 g for 10 min. Of 
the 24-hour urine collection, three urine tubes will be 
collected, of which one tube will be partially acidified. All 
blood and urine samples will be subsequently aliquoted 
by technicians and shipped to the core laboratory for 
storage in −80°C (−112°F) freezers (Panasonic, ‘s-Herto-
genbosch, The Netherlands) (table 1). Blood and urine 
samples will be analysed in the following years for multiple 
research questions that will arise.
Participants will be asked to collect a faeces sample the 
day prior to the TransplantLines visit. A FecesCatcher 
(TAG Hemi VOF, Zeijen, The Netherlands) will be sent 
to the patient’s home, and faeces sample will be collected 
in appropriate tubes and frozen immediately after collec-
tion. The participant will transport the faeces sample in 
cold storage (with ice cubes or in a cooler) to the Trans-
plantLines visit the following day. Subsequently, the faeces 
sample will be immediately stored at −80°C (−112°F). 
Faeces samples will be primarily used for microbiome 
analyses. Solid organ transplant recipients have a shift 
in the gut microbiome with a decrease in predominant 
organisms, a loss of bacterial diversity and emergence of 
new dominant population. These may result in increased 
risk of infection, rejection and mortality. Therefore, we 
would like to examine the gut microbiome in relation to 
the development of health problems after transplantation.
Additional blood and urine samples will also be 
collected in the event of worsening graft function and an 
organ transplant biopsy is indicated. Prior to the biopsy, 
one serum tube of 10 mL, two EDTA samples of 10 mL, 
one citrate tube of 6 mL, one lithium-heparin tube of 
10 mL and one PAXgene tube of 10 mL will be collected. 
At the same time, one serum tube of 10 mL, one EDTA 
sample of 10 mL and one spot urine sample of 10 mL 
will be collected and directly stored on ice to prevent 
(ongoing) in vitro complement activation.
Furthermore, during transplant surgery and trans-
plant biopsies, tissue samples will be collected of the 
transplanted organ and surrounding tissues, including 
fat, skin, ureter, tracheal, biliary, and arterial and venous 
tissues, that have been discarded as pathological waste.
Clinical and laboratory characteristics
Clinical laboratory measurements requested by the physi-
cian will be included in the study database on patient 
consent. Most study visits are at the outpatient clinic, and 
for these visits blood samples will be taken fasting in the 
morning. It is unlikely that at these study visits multiple 
labs will be obtained on the same day, but if they are taken 
only the lab obtained at the time of the study visit will 
be included in the database. In the likely rare case that 
multiple labs are taken on the day of a study visit, this will 
Table 1 Overview of stored samples per participant in the 
TransplantLines biobank
Sample Colour code Tube size n Temperature
Serum Red 1500 µL 4 −80°C/−112°F
EDTA 
plasma
Purple 1500 µL 6 −80°C/−112°F
Buffy coat Purple NA 1 −80°C/−112°F
Blood with 
RBC
Purple 1500 µL 2 −80°C/−112°F
Lithium-
heparin
Green 1500 µL 4 −80°C/−112°F
Citrate Blue 500 µL 4 −80°C/−112°F
PAXgene Transparent 2.5 mL 1 −80°C/−112°F
24-hour 
urine




Yellow 2000 µL 2 −80°C/−112°F
Faeces Black 20 mL 1 −80°C/−112°F
Nails Purple 0.5 µL 1 −80°C/−112°F
Hair Purple 2000 µL 1 −80°C/−112°F
NA, not applicable; RBC, red blood cell.
 o
n
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likely be a sign of an acute event that occurred after the 
study visit and it will then later on be linked to the data-
base as the event that occurred. At the visit for transplant 
surgery, multiple labs will be obtained on the same day. 
On that day, only the lab results available from the samples 
which are taken at the same time of sampling during 
surgery to provide for samples that will be included in the 
biobank will be linked to the database. These lab results 
are recognisable by the routine assays that are performed, 
because they are more extensive and include other 
routine lab results than the routine lab results available 
from the samples taken at other times on the same day. 
Demographic characteristics along with data on medica-
tion use will be provided by the participants and will be 
verified using electronic hospital records. Medical infor-
mation including donor and recipient information at 
the time of transplantation, underlying disease, hospital 
admissions, complications after transplantation, further 
surgical or other interventional treatments, comorbid-
ities, graft failure, and mortality will be extracted from 
electronic hospital records.
Questionnaires
Biobank data will be expanded with an extensive set of 
questionnaires to collect data on physical, psycholog-
ical and social impact of undergoing a transplantation 
(figure 3). Transplant candidates will be asked to fill out 
a comprehensive questionnaire during screening prior to 
transplantation and at 1-year post-transplantation. Trans-
plant recipients with a functional graft for more than 
1 year post-transplantation and who received the solid 
organ prior to the start of the TransplantLines study will 
be asked to complete the same questionnaire. A subset of 
questionnaires will be provided at other predefined time-
points, that is, at 3, at 6 months and at 2 years after trans-
plantation. Topics addressed by questionnaires include, 
among others, nutritional intake and diet, health-related 
quality of life, lifestyle factors such as physical activity, 
sleep quality and smoking behaviour, psychological 
impact such as anxiety, depression, coping and well-being, 
and social impact such as employment and family rela-
tionships. Specification of all the different questionnaires 
with related subject is shown in table 2. Questionnaires 
will be sent digitally or by mail, as requested. During study 
Figure 3 Overview of the three main pillars of the 
TransplantLines study, that is, questionnaires, biobank 
and tests. The collection of data in these pillars at multiple 
timepoints will allow investigation of whether biomarkers 
at baseline can better predict the occurrence of adverse 
outcomes and whether correction could possibly result in an 
improved survival.
Table 2 List of questionnaires in the TransplantLines study
Questionnaires Related subject
EQ6D60 EuroQoL six dimensions
VAS61 Visual Analogue Scale
SF3662 Short Form-36 Health Survey
SQUASH63 Short Questionnaire to Assess Health-
Enhancing Physical Activity
BAASIS64 Basel Assessment of Adherence to 
Immunosuppressive Medications Scale
MTSOSDS-R5965 Modified Transplant Symptom 
Occurrence and Symptom Distress scale
CIS66 Checklist Individual Strength (Fatigue)
PSQI67 Pittsburgh Sleep Quality Index
STAI668 Short form State Trait Anxiety Inventory
PHQ969 Patient Health Questionnaire (Depression)
CFQ70 Cognitive Functioning Questionnaire
WHO-571 World Health Organization-5 (Well-Being 
Index)
TxEQ72 Transplant Effects Questionnaire
Mastery Scale73 Pearlin Mastery Scale
UCL-47 Utrecht Coping List-47
USER-P Utrecht Scale for Evaluation of 
Revalidation-Participation
Work Participation in Labour
WRFQ74 Work Role Functioning Questionnaire
FAD Family Assessment Device





DAG75 DArmGezondheid (Bowel Health) 
Questionnaire
FFQ76 Food Frequency Questionnaire
LIVAS Scale for 
Physical Self-
Efficacy movement
Lichamelijke vaardigheden schaal, Dutch 
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visits, all questionnaires will be checked by a trained inves-
tigator for completeness and validity.
Standard assessments
Blood pressure (mm Hg) will be measured according to 
a standard clinical protocol using an automatic device 
(Philips Suresign VS2+, Andover, Massachusetts, USA). 
To prevent a white-coat effect, participants will be seated 
during which blood pressure and heart rate will be 
measured four times, with an interval of 3 min between 
measurements. Hereafter, participants will be asked to 
stand up straight for 1 min, after which blood pressure 
and heart rate measurements will be repeated once in 
standing position. Measurements will be performed with 
participants being on their regular medication, including 
antihypertensive drugs at trough.
Anthropometry measurements will include body 
weight, body length, and waist and hip circumference. 
Body weight (kg) will be measured in lightweight clothing 
without shoes using a calibrated digital measuring scale 
(seca 877, seca, Hamburg, Germany). Height (cm) will 
be measured using a wall-secured stadiometer (seca 222). 
Waist and hip circumference (cm) will be calculated using 
a measuring tape roll with standardised retraction mech-
anism (seca 201). Waist circumference will be measured 
mid-way between the lowest rib and the iliac crest with the 
participant in standing position. Hip circumference will 
be determined at the maximum circumference over the 
trochanter major. All anthropometry measurements will 
be assessed twice, with inclusion of a third measurement 
contingent on a difference of more than half a kilogram 
in weight or more than 1 cm in length.
Hand grip strength will be assessed with the Jamar 
Hydraulic Hand Dynamometer (Patterson Medical 
JAMAR 5030J1, Warrenville, Canada).19 Participants will 
be instructed to sit in a chair with their shoulders in 
adduction, their arms rotated into neutral position, their 
elbows flexed to 90°, and forearms and wrists held in 
neutral position. Hereafter, participants will be instructed 
to perform a maximal isometric contraction. Hand grip 
strength will be tested three times with an interval of 30 s 
rest for recovery between each attempt. The dominant 
hand will be stated in all measurements. Furthermore, to 
create uniformity among assessments, the second handle 
position of the hand dynamometer will be used, which 
has been shown to be the most accurate position.20
Lung function will be measured by means of an Asma-1 
handheld spirometer (Vitalograph, Buckingham, UK).21 
Of all participants, forced expiratory volume in 1 s, as a 
marker of lung function, will be recorded.
Body composition will be determined using a multifre-
quency bioelectrical impedance device (BIA, Quadscan 
4000, Bodystat, Douglas, British Isles) at 5, 50, 100 and 
200 Hz, which allows to distinguish between lean body 
mass and fat body mass taking into account differences 
in volume status.22 The main outcome variables from 
the BIA are estimated fat mass, fat-free mass and body 
fat percentage. In brief, the BIA measurement will be 
performed with the participant in supine position with 
arms and legs abducted from the body. Sensor electrodes 
will be placed on the dorsum of the right hand and 
feet, with a minimal distance of 5 cm between the elec-
trodes. Measurement will not be executed if the partic-
ipant has a temperature exceeding 37.9°C/100.2°F or 
has a functioning implantable cardioverter-defibrillator/
pacemaker.
Advanced glycation endproducts (AGEs) will be deter-
mined using an AGE Reader SU (DiagnOptics Technol-
ogies, Groningen, The Netherlands).23 The AGE Reader 
SU measures skin autofluorescence using the character-
istic fluorescent properties of certain AGEs to estimate 
the level of AGE accumulation in the skin. AGEs have 
been implicated in the pathogenesis of vascular damage 
and cardiovascular disorders and aid in characterising 
the cardiovascular risk profile of transplant recipients.24
Transplant recipients are known to be at increased 
risk for cutaneous malignancies, mainly related to long-
term use of immunosuppressive medication.25 To iden-
tify which transplant recipients are especially prone to 
develop dermatological health problems, a detailed 
dermatological history with emphasis on malignancies 
and subsequent treatment will be obtained. Next, a stan-
dardised dermatological examination will be performed 
by the trained investigator. The dermatological examina-
tion includes the determination of eye colour, natural 
hair colour at adolescence and skin type according to the 
classification of Fitzpatrick.26 In addition, the presence 
and quantity of lentigines, moles, freckles and warts are 
examined.
To assess frailty, the Clinical Frailty Scale (CFS) will be 
scored at study visits by the trained investigator. The CFS 
is a validated frailty measurement, and frailty is scored 
based on clinical judgement on a continuous scale from 1 
(very fit) to 9 (terminally ill). A CFS score of ≥5 is gener-
ally considered frail.27
To assess nutritional status, a Patient-Generated Subjec-
tive Global Assessment (PG-SGA, PT-Global, Philadelphia, 
USA) will be scored.27 28 The PG-SGA is a patient-centred 
adaptation of the original Subjective Global Assessment. 
The different domains assessed by the PG-SGA are (1) 
changes in body weight, (2) changes in nutritional intake, 
(3) symptoms which negatively influence intake, absorp-
tion and utilisation of nutrients, (4) level of activities and 
function, (5) conditions that increase nutritional risk 
or requirements, (6) metabolic stress, and (7) physical 
examination. Based on the PG-SGA score, subjects can be 
classified as well-nourished, moderately malnourished or 
severely malnourished.
randomisation and additional physical and cognitive tests
In addition to standard assessments, participants will 
receive additional physical tests or cognitive tests at 
their study visit at 12 months post-transplantation or 
at the first study visit if it concerns transplant recipi-
ents with a functioning graft for more than 1 year who 
were transplanted before the start of TransplantLines. 
 o
n




pen: first published as 10.1136/bmjopen-2018-024502 on 31 December 2018. Downloaded from 
7Eisenga MF, et al. BMJ Open 2018;8:e024502. doi:10.1136/bmjopen-2018-024502
Open access
Participants will be randomised (1:1 ratio) into either 
the ‘physical’ arm or the ‘cognitive’ arm of the study. 
Randomisation will be performed for each transplant 
programme separately to ensure balanced randomisa-
tion of subjects for each type of solid organ transplant. 
Participants randomised into the ‘physical’ arm of the 
study protocol will be asked to accomplish a standing 
balance test, a 2-Minute Walk Test (2MWT), a 4-Metre 
Walk Test (4MWT), a dexterity test, a Five Time Sit To 
Stand (FTSTS) test, Timed Up and Go (TUG) test, a 
rigorous neurological examination and a breath anal-
ysis. With inclusion of the first four tests together with 
the hand grip strength, the five physical components 
of the National Health Institute Toolbox for motor 
assessment are being assessed.29 A subset of these tests 
will also be performed at 6 months post-transplanta-
tion study visit in all solid organ transplant recipients. 
Participants randomised into the ‘cognitive’ arm of 
the study protocol undergo a series of neuropsycho-
logical tests performed by a trained neuropsychologist 
or master student neuropsychology under the super-
vision of a trained neuropsychologist. The tests are 
administered in a quiet room with no disturbances. 
For timed tests, a digital clock is used. The tests are 
performed in a fixed order and no feedback regarding 
the results is given to the participant during adminis-
tration. An overview of the different tests performed 
in TransplantLines including the neuropsychological 
tests is specified in table 3. A subset of the neuropsy-
chological tests will also be performed at 3 months 
Table 3 Overview of the different tests performed in TransplantLines study per study protocol
Parameter/Test Details
General (all protocols)
  General parameters Collection of Biobank material and evaluation of questionnaires, check quality of 
data
  Blood pressure Using an automatic or semiautomatic device
  Weight Using digital measuring scale
  Length Using measuring tape fixed to the wall
  Waist and hip size Using measuring tape roll
  BIA Bioimpedance analysis (Quadscan 4000)
  SAF Skin autofluorescence (AGE Reader SU)
  Dermatological questionnaire After physical examination by student researcher
  Clinical Frailty Scale After physical examination by student researcher
  PG-SGA Scored Patient-Generated Subjective Global Assessment
  Lung function Using spirometry (Vitalograph Asma-1)
  Breath analysis Using QuinTron BreathTracker
Physical protocol
  Balance test Using Axivity accelerometer
  Hand grip Using hydraulic handheld dynamometer
  Physical strength Multiple muscle groups, using digital dynamometer
  Sensibility tests Using pin-prick, monofilament and biothesiometer
  Tremor analysis Using Tetras scale and Axivity accelerometers
  Manual dexterity Using dexterity PEG-Board
Cognitive protocol
  Nederlandse Leestest voor Volwassenen Dutch version of the National Adult Reading Test 
  Digit Span Subtest of the Wechsler Adult Intelligence Scale IV 
  15 Words Test Dutch version of Ray Auditory Verbal Learning Test 
  Cognitive Screening Test Cognitive Screening Test (20)
  Trail Making Test
  Clock-Drawing Test
  Symbol Digit Modalities Test
  Letter Fluency Test Dutch version of the Controlled Word Association Test 
  Word Fluency Test Subtest of the Groningen Intelligence Test
  Key Search Test Subtest of the Behavioural Assessment of the Dysexecutive Syndrome 
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post-transplantation in all solid organ transplant 
recipients.
Physical protocol measurements and tests
The standing balance test will be performed with an accel-
erometer (Axivity, Newcastle, UK), attached to the lower 
back. The standing balance test has been described 
in detail previously.29 Balance will be evaluated in five 
different positions: (1) feet together on hard surface, eyes 
open; (2) feet together on hard surface, eyes closed; (3) 
feet together on foam surface (Balance Pad Elite; Airex 
Specialty Foams, Aargau, Switzerland), eyes open; (4) 
feet together on foam surface, eyes closed; and (5) feet 
in tandem stance, eyes open. Participants will be asked to 
have arms crossed on their chest and each position will be 
tested for 50 s. On failure, recording the time to failure, a 
second attempt will be performed. In case of non-success 
at the second attempt, the test will be discontinued.
Endurance will be tested with a 2MWT.30 The 2MWT 
has been shown to be highly correlated, without compro-
mising validity and reliability, with the 6 min walking test, 
an important submaximal exercise test.31 32 To calculate 
the distance covered by subjects on the 2MWT, two pylons 
are set 15 m apart and subjects are instructed to walk as 
fast as possible without running, until the investigator 
commands them to stop. Participants are updated on the 
remaining time after 1.00 and 1.45 min, and the final 5 s 
are indicated by a countdown. The total walking distance 
in 2 min is recorded in total metres covered, with the 
remaining scored in centimetres.
Locomotion, measured as gait speed, will be tested with 
a 4MWT. Gait speed is a simple measure to summarise 
the overall disease burden and disability.33 34 In brief, two 
pylons will be set 4 m apart and subjects instructed to walk 
at a usual pace. Seconds from start to end of the 4 m will 
be recorded. The 4MWT is measured twice after the first 
trial round.
Manual dexterity will be measured in all transplant 
recipients using the 9-Hole Peg Test (9-HPT, Sammons 
Preston Rolyan, Chicago, Illinois). The 9-HPT requires 
participants to repeatedly place and remove nine pegs 
into nine holes, one at a time, as quickly as possible, and 
is considered to be the gold standard metric for manual 
dexterity.
Functional mobility will be tested in participants using 
the FTSTS and TUG. The FTSTS is a functional perfor-
mance measure of leg strength or the force-generating 
capacity of the muscle by using the body’s weight for 
resistance during functional activities.35 The FTSTS will 
be executed three times after a first trial round. Partic-
ipants will be instructed to stand up five times as fast as 
possible, from sitting position with their feet flat on the 
floor and arms folded across the chest. Measurements 
start on command, and subsequently the time required to 
stand up and return sitting is recorded. Time is measured 
in seconds and this task is repeated five times.36
The TUG is a basic test for functional mobility and is 
based on strength, coordination and balance.37 For the 
test, a pylon and a chair will be put 3 m apart. The test 
will be performed four times, with the first round being 
a trial. Participants are instructed to stand up from the 
chair without support of the arms, subsequently walk with 
their normal gait speed around the pylon and go back 
to the chair to sit down again. In the case where partic-
ipants use a walking aid in normal day life, the test will 
be performed with the use of a walking aid. The TUG is 
measured in seconds, from the moment the participant is 
instructed to get up until the moment the participant sits 
down again.
Transplant recipients have an increased susceptibility 
to develop peripheral neuropathy and tremor, mainly 
due to the continuous use of immunosuppressive medi-
cation, especially calcineurin inhibitors.38 39 Therefore, 
an extensive neurological examination will be performed 
and will consist of strength testing, classifying polyneu-
ropathy and tremor quantification. Detailed strength 
testing of different muscle groups (feet flexion/exten-
sion, hip flexion, biceps flexion and wrist extension) will 
be performed with a digital dynamometer (CIT Tech-
nics, Haren, The Netherlands).40 Hereafter, sensibility 
tests will be performed using a pin-prick and monofil-
ament pen (Novo Nordisk BV, Alphen aan den Rijn, 
The Netherlands) on bare skin five times per measure-
ment at the dorsal side of the first phalange of both feet 
with the subject closing their eyes. On failure of sensi-
bility, the dorsal side of the foot and lower limb will be 
tested. Proprioception will be measured by moving the 
first phalange of both feet in dorsal flexion and plantar 
flexion five times with the participants closing their eyes. 
On failure, the dorsal side of the foot and the index 
finger will be measured.
Vibration sense will be measured using a handheld 
biothesiometer (Biomedical Instrument, Ohio, USA).41 
The biothesiometer has a rubber tractor that vibrates 
at 100 Hz when operating from 50 Hz mains. In brief, 
participants will be measured in a supine position on 
a bed barefoot. The vibrating tractor will be applied 
bilaterally to four different measurement points of the 
participants: top of the hallux, forefoot, lateral malleoli 
and wrist. Before applying the vibrating tractor to the 
points to be tested, the amplitude of the vibrating tractor 
is increased from zero to the point where the vibration 
is perceptible and beyond the threshold to the highest 
amplitude possible to familiarise participants with the 
sensation. For the measurement, the participants will be 
asked to concentrate on the test and report the first sensa-
tion of the vibration by saying ‘Stop’. Each measurement 
point is tested twice. If the difference between the first 
two measurements is greater than 20%, the measurement 
point is tested a third time.
Prior to tremor quantification, participants will be 
asked to complete part C of the Fahn-Tolosa-Marin 
Tremor Rating Scale, which involves tremor-related func-
tional disability.42 The questionnaire involves speaking, 
bringing liquids to the mouth, eating, hygienic care, 
dressing, writing, work and household-related tasks. 
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The questionnaire uses a 5-point scale, with ‘0=no func-
tional ability’ and 4= ‘severe disability, the task cannot be 
executed’.
To quantify tremor, two accelerometers (UMCG, Gron-
ingen, The Netherlands) will be attached to the dorsal 
side of both hands. The accelerometers will record move-
ment in the coronal, transversal and sagittal planes, as 
well as linear acceleration and deceleration in both hands 
continuously, during the measurements. Amplitudes 
and frequency of these measurements will be recorded 
on a stand-alone computer. Participants will be asked to 
assume seven different positions while seated, which are 
measured for 30 s each: arms down, wrists extended; arms 
forward, wrists and fingers relaxed; arms forward, wrists 
and fingers in 0 position; index fingers pointed towards 
each other; bilateral finger-nose task; weighted arms 
down with wrists expanded; and weighted arms forward 
with wrists and fingers extended.
Finally, participants will be asked for collection of a 
breath sample in which hydrogen and methane will be 
measured with the QuinTron BreathTracker (Milwaukee, 
Wisconsin, USA).43 Both hydrogen and methane are 
exclusively formed by anaerobic fermentation in the gut, 
and therefore can be used as markers for methanogenic 
microflora in transplant recipients.44
Cognitive protocol measurements and tests
The Cognitive Screening Test is a Dutch screening test for 
dementia, measuring orientation in time and place, and 
memory for common facts.45 The questionnaire consists 
of 20 items (eg, date of birth, name of the reigning 
monarch, season) and the score is calculated as the total 
number of questions answered correctly, with a maximum 
of 20.
Nederlandse Leestest voor Volwassenen is the Dutch version 
of the National Adult Reading Test. The participant has 
to read aloud a list of 50 irregularly spelled words. The 
total score on the test is converted into an estimation of 
the premorbid IQ.46
The Clock-Drawing Test is a cognitive screening instru-
ment.47 Participants are asked to draw a clock and set the 
time to ‘a quarter to two’. A maximum total score of 14 
can be achieved.
The 15 Words Test, the Dutch version of the Rey Audi-
tory Verbal Learning Test, measures verbal memory.48 In 
this task a set of 15 unrelated words is presented to the 
participant, consecutively over five trials. Participants are 
asked to recall as many words as possible immediately 
after each trial (immediate recall). The score is the total 
words recalled in five trials, with a maximum of 75. After 
20 min, participants are asked to recall as many of the 15 
words as possible (delayed recall). Additionally, a recog-
nition task will be performed. Participants are presented 
with a list of 30 words and are asked which words they 
recognise from the list they have been presented before.
Digit Span is a subtest of the Wechsler Adult Intelligence 
Scale IV.49 This subtest consists of two tasks, the Digit 
Span Forward and the Digit Span Backward. The Digit 
Span Forward is a task for immediate auditory memory 
span. In this task, participants are asked to repeat a series 
of numbers in the same order as the examiner did. The 
Digit Span Backward measures working memory. Partici-
pants have to repeat the presented numbers in reversed 
order. The score is the total strings repeated, with a 
maximum of 32.
The Word Fluency Test, a subtest of the Groninger 
Intelligentie Test 2, is a verbal task measuring semantic 
memory.50 Participants are asked to name as many words 
within a certain category within 1 min. The total score 
per category (respectively animals and professions) was 
calculated.
The Controlled Oral Word Association Test is a verbal 
task measuring executive control.51 Participants have to 
name as many words as possible that start with a specific 
letter within 1 min. In the meantime, participants have to 
comply to several rules that are given beforehand. The 
total scores from three different starting letters (D-A-T) 
were calculated.
The Symbol Digit Modalities Test measures psychomotor 
speed.52 The test consists of matching symbols and 
numbers as fast as possible in 90 s. The total score of 
correct matches is calculated.
The Trail Making Test (TMT) consists of two parts: 
Trail Making Test-A (TMT-A) and Trail Making Test-B 
(TMT-B). TMT-A is a measure of attention and informa-
tion processing speed. This task involves connecting 25 
numbers in ascending order, as quickly as possible. The 
TMT-B is a measure of divided attention and cognitive 
flexibility. In this condition, numbers as well as letters have 
to be connected in ascending order, alternating between 
numbers and letters (1-A-2-B- and so on). Both parts of 
the test are timed to completion (number of seconds).
The Key Search Test is a subtest of the Behavioural Assess-
ment of the Dysexecutive Syndrome and assesses the 
ability to plan and monitor progress. Participants are 
presented with a square which represents a field in which 
‘keys have been lost’. Participants must show how they 
would search the field to find the keys. Searching strategy 
is scored by means of functionality and a maximum total 
score of 16 can be achieved.
outcomes
The primary outcomes of the TransplantLines study are 
all-cause mortality and graft failure, which are defined 
as death due to failure of the transplanted organ, return 
to organ replacement therapy or retransplantation. The 
secondary outcomes will be cause-specific mortality, 
cause-specific graft failure and rejection. The tertiary 
outcomes will be other health problems, including 
diabetes, obesity, hypertension, hypercholesterolaemia 
and cardiovascular disease, and disturbances that relate 
to quality of life, for example, physical and psychological 
functioning, quality of sleep, and neurological problems 
such as tremor and polyneuropathy.
The TransplantLines biobank study aims to identify 
the risk factors for health problems and patient-centred 
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outcomes (eg, adverse drug events, lifestyle, quality of life, 
social participation, physical and cognitive functioning). 
Due to the nature of the biobank, not all research ques-
tions are predefined and will arise during the course of 
inclusion. In contrast to many other studies, Transplant-
Lines also aims to identify and ameliorate complaints 
experienced by transplant recipients, such as tremors and 
diarrhoea, which to date have largely been overlooked by 
clinicians.
data management
Analysis, and access to data and samples
Data will be recorded digitally in an electronic case 
report form in a certified Electronic Data Capture and 
Clinical Data Management System (Utopia Data Manage-
ment System V.1.13.6, Research Data Support, UMCG). 
Data entry is performed by the trained investigators. The 
trained investigator who performed assessments at the 
study visit of a participant is responsible for data entry 
of that participant. All data are later checked again by 
the trained investigators and are subsequently stored 
anonymously in a secured electronic environment. The 
TransplantLines database will be linked to registries and 
databases of the Dutch Health Database, Netherlands 
Comprehensive Cancer Organisation, Central Bureau of 
Statistics, InterAction Database, Dutch Nephrology Regis-
tration/Registration Renal Replacement Therapy (Nefro-
visie, Renine), Nationwide Network and Registry of 
Histo- and Cytopathology in the Netherlands (PALGA), 
National Organ Transplant Registry, PHARMO Institute 
for Drug Outcomes Research, Routine Outcome Moni-
toring, and the Dutch Institute of Clinical Auditing data-
base through a generic layer. A data management board 
will be formed to maintain data infrastructure, construct 
material transfer agreements, and to govern use of the 
TransplantLines biobank and database. Extractions 
from TransplantLines database will be performed using 
a retrieval suite in Utopia software package only after 
approval of the data management board. Data will always 
be extracted anonymously. SPSS Statistics V.23, R V.3.2.3 
(CRAN, Vienna, Austria), STATA V.14.1 or a similar statis-
tical package will be used for analysis. Data collection and 
management is performed in accordance with the Hand-
book for Adequate Natural Data Stewardship (Nether-
lands Federation of University Medical Centers, 2017). 
A team consisting of medical doctors of the different 
fields involved, called Research Team TransplantLines, is 
installed to decide and prioritise who will get access to 
the samples and data of the TransplantLines biobank and 
cohort study. Use of samples and data can be requested 
by internal and external researchers against a reasonable 
fee. All samples are stored at −80°C and access are logged 
in a linked database. The logging system also provides for 
registration of multiple access and the number of freeze–
thaw cycles that the samples have undergone. Multiple 
access to samples is possible, but for each specific project 
a new request needs to be performed and approved by 
the Research Team TransplantLines. The data available 
from the assays performed on the provided samples will 
be linked to the TransplantLines database and be made 
available to researchers in the certified Electronic Data 
Capture and Clinical Data Management System, which 
will allow for evaluation and statistical analyses. This envi-
ronment will also monitor and log data handling and 
store the results of the analyses.
Missing data handling
Concerning treatment of missing data and inability to 
generate data from missing samples, we will apply statis-
tical methods using maximum likelihood and multiple 
imputation, which are now standard for dealing with 
loss of participants and missing data.53 These methods 
provide more consistent and efficient estimates of popu-
lation parameters than methods relying on complete 
cases, mean imputation, last observation carried forward 
or single-imputation regression methods.53–56 As advised 
in authoritative reports, these analyses will be comple-
mented with sensitivity analyses to assess robustness of 
findings.57–59
dIsCussIon
The TransplantLines prospective cohort study seeks 
to identify the risk factors for the development of 
long-term health problems after transplantation, and 
ultimately to develop new and innovative interven-
tions to improve graft survival, patient survival and 
quality of life after transplantation. The Transplant-
Lines biobank will encompass all solid organ trans-
plantations and living organ donors. It will consist of 
follow-up data from all fields that are involved in organ 
transplantation: internal medicine, surgery, gastro-
enterology, hepatology, pulmonology, cardiology, 
dermatology, neurology, occupational medicine, chil-
dren’s medicine, (neuro)psychology, physiotherapy 
and social work.
Although short-term transplant outcomes have 
improved in the last decades, graft and recipient life 
expectancy remains limited. In the TransplantLines 
study, data and samples will be collected before, 
during and after transplantation to gather further 
insight into the impact of transplantation on trans-
plant recipients. In addition, we aim to pre-emptively 
detect those transplant recipients who are at increased 
risk to develop graft failure or health problems. By 
investigating a wide range of clinical, social/psycho-
logical and biochemical parameters, this study aims to 
contribute to increased transplant survival and patient 
survival, but also to an increased quality of life and a 
more patient-centred approach to transplant care.
Our study has strengths and limitations. The major 
strengths of this study are the collection of extensive 
data on a myriad topics related to transplantation, the 
inclusion of all types of solid organ transplant recipi-
ents and living organ donors, and a study with a long 
follow-up to assess many relevant clinical outcomes. 
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The limitations of the current study are that it is a 
single-centre study and that residual confounding 
cannot be excluded in analyses due to its observa-
tional design. Another limitation is that transplant 
recipients with limited language skills and/or poor 
comprehension are excluded because these patients 
are likely those who are at higher risk of poor compli-
ance and high risk of social behaviour, which would 
possibly have worse outcomes. A further limitation 
is that our infrequent collection of biobank samples 
may limit utility in detecting biomarkers for routine 
monitoring of transplant health, and detection of 
suitable biomarkers may only be possible if sampling 
happens to fall near the time of a clinical event. It may 
be considered a strength that in addition to taking 
samples at fixed timepoints, we also take samples when 
biopsies are performed, both at the time of protocol 
biopsies and at the time of biopsies taken at clinical 
indication, usually because of worsening of transplant 
function, with suspicion of acute or chronic rejection.
TransplantLines may serve as a basis for hypothesis-gen-
erating studies that yield insights into a wide range of clin-
ical, social/psychological and biochemical parameters in 
solid organ transplant recipients as well as living donors. 
Biomarkers may be identified to develop more individ-
ualised immunosuppressive treatment. This will lead to 
novel clinical trials in transplantation and patient-tailored 
approaches for new treatment options. Furthermore, the 
results of TransplantLines may serve to identify new modi-
fiable risk factors and lifestyle factors in transplantation. 
Ultimately, this information will likely contribute to a 
more individualised treatment for transplant patients and 
improved living donor screening and follow-up. Thereby 
we aim to qualitatively and quantitatively improve 
outcomes after transplantation.
study stAtus
Data collection is in progress.
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